T. Nagy

发表

Cholesterol Potentiates ABCG 2 Activity in a Heterologous Expression System : Improved in Vitro Model to Study Function of Human ABCG 2

L. Szente, D. Méhn, T. Janáky, 2007 .

Cholesterol Potentiates ABCG2 Activity in a Heterologous Expression System: Improved in Vitro Model to Study Function of Human ABCG2

L. Szente, D. Méhn, T. Janáky, 2007, Journal of Pharmacology and Experimental Therapeutics.

Ivermectin interacts with human ABCG2.

E. Kis, P. Krajcsi, P. Szabó, 2011, Journal of pharmaceutical sciences.

Effect of Membrane Cholesterol on BSEP/Bsep Activity: Species Specificity Studies for Substrates and Inhibitors

L. Szente, K. Herédi-Szabó, E. Kis, 2009, Drug Metabolism and Disposition.

Successful Treatment of Solitary Bone Metastasis of Non-Small Cell Lung Cancer with Bevacizumab and Hyperthermia

A. Szász, I. Láng, T. Nagy, 2012, Pathology & Oncology Research.

The expressions of ABCC4 and ABCG2 xenobiotic transporters in human keratinocytes are proliferation-related

A. Kurunczi, L. Kemény, K. Kis, 2011, Archives of Dermatological Research.

Tumor cells expressing membrane-bound tumor necrosis factor activate macrophages and have a compromised growth in immunosuppressed and immunodeficient mice.

E. Duda, I. Juhász, J. Hunyadi, 2003, Cancer letters.

Pathophysiological effects of human TNF‐alpha‐producing tumor xenografts in immunosuppressed mice

E. Duda, C. Vízler, P. Vegh, 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Mouse Bsep ATPase Assay: A Nonradioactive Tool for Assessment of the Cholestatic Potential of Drugs

E. Kis, P. Krajcsi, T. Nagy, 2009, Journal of biomolecular screening.

Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab

E. Hitre, I. Láng, V. Adleff, 2012, Pharmacogenetics and genomics.

Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.

Z. Szentirmay, E. Hitre, I. Láng, 2013, European journal of cancer.

Receptor-like properties of the 26 kDa transmembrane form of TNF.

E. Duda, Á. Domonkos, T. Nagy, 2001, European cytokine network.

Membrane Structure Modulation , PKC α Activation and Anti-Cancer Activity of Minerval

P. Escribá, Silvia Terés, Jordi Martínez, 2004 .

D06 Differences between ivermectin and moxidectin related to their affinities for multidrug resistance proteins (MRP1, 2 and 3)

M. Alvinerie, P. Krajcsi, T. Nagy, 2006 .

Membrane Assays to Characterize Interaction of Drugs with ABCB1

A. Kurunczi, Z. Fekete, F. Fülöp, 2015, The Journal of Membrane Biology.

Membrane Structure Modulation, Protein Kinase Cα Activation, and Anticancer Activity of Minerval

P. Escribá, Silvia Terés, Jordi Martínez, 2005, Molecular Pharmacology.

The Gβγ Dimer Drives the Interaction of Heterotrimeric Gi Proteins with Nonlamellar Membrane Structures*

P. Escribá, J. Casas, G. Martorell, 2004, Journal of Biological Chemistry.

Interaction of macrocyclic lactones with the multidrug transporters: the bases of the pharmacokinetics of lipid-like drugs.

M. Alvinerie, S. Orlowski, P. Krajcsi, 2009, Current drug metabolism.

Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer

E. Hitre, T. Pintér, I. Láng, 2018, Pathology & Oncology Research.

Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3).

M. Alvinerie, S. Orlowski, P. Krajcsi, 2006, Chemico-biological interactions.

Signaling and Reverse Signaling in the Tumor Necrosis Factor/TNF Receptor System

D. Männel, G. Eissner, E. Duda, 2005 .

Flow cytometric cytotoxicity assay for measuring mammalian and avian NK cell activity.

E. Duda, C. Vízler, T. Nagy, 2002, Cytometry.

Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance

K. Német, E. Kis, É. Molnár, 2008, Annals of the rheumatic diseases.

Synergistic Effect of Avemar on Proinflammatory Cytokine Production and Ras‐Mediated Cell Activation

E. Kiss-Toth, E. Duda, E. Qwarnstrom, 2005, Annals of the New York Academy of Sciences.

[Effect of imatinib treatment of gastrointestinal stromal tumors].

G. Bodoky, J. Horti, L. Trón, 2003, Orvosi hetilap.

G protein-membrane interactions I: Gαi1 myristoyl and palmitoyl modifications in protein-lipid interactions and its implications in membrane microdomain localization.

P. Escribá, X. Busquets, D. J. López, 2015, Biochimica et biophysica acta.

The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab

E. Hitre, I. Láng, B. Budai, 2012, Angiogenesis.

Calcein assay: a high-throughput method to assess P-gp inhibition

I. Wilhelm, I. Krizbai, P. Couraud, 2011, Xenobiotica; the fate of foreign compounds in biological systems.

[Changes in renal function during bisphosphonate treatment of breast cancer patients].

E. Hitre, I. Láng, Z. Horváth, 2008, Magyar Onkológia.

Membrane structure modulation, protein kinase C alpha activation, and anticancer activity of minerval.

P. Escribá, J. Casas, P. Kasprzyk, 2005, Molecular pharmacology.

Membrane Structure Modulation, Protein Kinase Cα Activation, and Anticancer Activity of Minerval

P. Escribá, J. Casas, P. Kasprzyk, 2005, Molecular Pharmacology.

Specific inhibition of the ABCG2 transporter could improve the efficacy of photodynamic therapy.

L. Kemény, A. Dobozy, Z. Bata-Csörgő, 2011, Journal of photochemistry and photobiology. B, Biology.